# Pharmacokinetics of SPI-2012 (Eflapegrastim) in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy

> **NCT03135951** · PHASE1 · COMPLETED · sponsor: **Spectrum Pharmaceuticals, Inc** · enrollment: 26 (actual)

## Conditions studied

- Breast Cancer
- Pharmacokinetics

## Interventions

- **DRUG:** SPI-2012

## Key facts

- **NCT ID:** NCT03135951
- **Lead sponsor:** Spectrum Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-11
- **Primary completion:** 2018-02-19
- **Final completion:** 2018-05-18
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2020-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03135951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03135951, "Pharmacokinetics of SPI-2012 (Eflapegrastim) in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03135951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*